In endometrial cancer-related studies, adiponectin treatment can downregulate ERK1/2 signaling, that is, through the ERK1/2-MAPK pathway, reducing cell viability and inhibiting cell proliferation in endometrial cancer cell lines [22]. The gene discussed is MAPK3; the disease is endometrial cancer.